- Home
- TYGO vs YARW Comparison
TYGO vs YARW Comparison
Compare TYGO & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYGO | YARW |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.0M | 114.6M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TYGO | YARW |
|---|---|---|
| Price | $1.10 | $38.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 25.9K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.12 | 33.33 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $103,536,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $21.68 | N/A |
| P/E Ratio | $111.00 | ★ N/A |
| Revenue Growth | ★ 91.68 | N/A |
| 52 Week Low | $0.93 | $31.55 |
| 52 Week High | $5.33 | $44.28 |
Technical Indicators
Market Signals| Indicator | TYGO | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 54.67 |
| Support Level | $0.93 | $35.50 |
| Resistance Level | $1.73 | $44.27 |
| Average True Range (ATR) | 0.07 | 2.78 |
| MACD | 0.03 | -0.46 |
| Stochastic Oscillator | 44.00 | 28.54 |
Price Performance
Historical ComparisonAbout TYGO Tigo Energy Inc.
Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.